Clearmind Medicine (CMND) 6-K 13 Jun 24 Condensed Interim Consolidated Financial Statements Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Apr. 30, 2024
Document Information Line Items
Entity Registrant Name	Clearmind Medicine Inc.
Document Type	6-K
Current Fiscal Year End Date	--10-31
Amendment Flag	false
Entity Central Index Key	0001892500
Document Period End Date	Apr. 30, 2024
Entity File Number	001-41557

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position (Unaudited) - USD ($)	Apr. 30, 2024	Oct. 31, 2023
Current assets
Cash and cash equivalents	$ 8,305,927	$ 5,427,739
Other receivables	69,506	104,320
Short-term investment (Note 3)		86,112
Prepaid expenses	210,609	40,403
Related parties (Note 4b)	105,022	136,002
Total current assets	8,691,064	5,794,576
Non-current assets
Property and equipment	624	1,727
Intangible assets	113,848	119,310
Restricted cash	40,182	37,675
Total non-current assets	154,654	158,712
Total assets	8,845,718	5,953,288
Current liabilities
Accounts payable and accrued liabilities	421,156	617,004
Due to related parties (Note 4a)	47,009	42,433
Derivative warrant liabilities (Note 5)	3,731,799	4,310,379
Total current liabilities	4,199,964	4,969,816
Total liabilities	4,199,964	4,969,816
Shareholders’ equity
Share capital and share premium (Note 6)	22,757,547	17,131,223
Warrants (Note 7)	459,341	459,341
Share-based payment reserve (Notes 8,9)	2,494,196	2,182,221
Accumulated other comprehensive loss	(21,250)	(21,250)
Accumulated deficit	(21,044,080)	(18,768,063)
Total shareholders’ equity	4,645,754	983,472
Total liabilities and shareholders’ equity	$ 8,845,718	$ 5,953,288

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Operating expenses
General and administrative		$ 980,549	$ 1,338,445	$ 2,137,062	$ 2,583,873
Research and development, net		322,956	317,572	550,434	905,202
Total operating expenses		1,303,505	1,656,017	2,687,496	3,489,075
Finance income (expenses)
Changes in fair value of derivative warrant liabilities (Note 5)		405,002	(360,557)	560,145	(360,557)
Unrealized gain (loss) on short-term investment (Note 3)		415,270	4,445	415,826	(58,749)
Realized loss on short-term investment (Note 3)		(423,438)		(423,438)
Foreign exchange gain (loss)		1,255	(60,952)	2,671	(95,356)
Other finance income, net		33,955	5,966	94,531	23,981
Total finance income (expenses)		432,044	(411,098)	649,735	(490,681)
Other income
Dividend received					16,555
Total other income					16,555
Loss before taxes		(871,461)	(2,067,115)	(2,037,761)	(3,963,201)
Tax expenses		(36,756)	(9,267)	(238,256)	(12,650)
Net Loss and Comprehensive loss		$ (908,217)	$ (2,076,382)	$ (2,276,017)	$ (3,975,851)
Loss per share, basic (in Dollars per share)		$ (0.28)	$ (16.62)	$ (0.96)	$ (39.62)
Weighted average number of shares for the purposes of basic loss per share (in Shares)	[1]	3,253,267	124,911	2,375,825	100,351
[1]On November 28, 2023, the Company effected a 1-for-30 reverse split of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share then held. All share data prior to the date of the reverse share split has been retrospectively adjusted.

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares		3 Months Ended		6 Months Ended
		Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Profit or loss [abstract]
Loss per share , diluted		$ (0.28)	$ (16.62)	$ (0.96)	$ (39.62)
Weighted average number of shares for the purposes of diluted loss per share	[1]	3,253,267	124,911	2,375,825	100,351
[1]On November 28, 2023, the Company effected a 1-for-30 reverse split of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share then held. All share data prior to the date of the reverse share split has been retrospectively adjusted.

Condensed Interim Statements of

Condensed Interim Statements of Changes in Shareholders’ Equity (Deficit) (Unaudited) - USD ($)		Share capital and share premium	Warrants	Share-based payment reserve	Accumulated other comprehensive income	Accumulated deficit	Total
Balance at Oct. 31, 2022		$ 6,706,644	$ 459,110	$ 1,896,724	$ (21,250)	$ (10,147,226)	$ (1,105,998)
Balance (in Shares) at Oct. 31, 2022	[1]	43,992
Net loss for the period						(3,975,851)	(3,975,851)
Issuance of common shares		$ 6,026,327		337,579			6,363,906
Issuance of common shares (in Shares)	[1]	38,462
Common shares and warrants issued to XYLO TECHNOLOGIES LTD. (formerly Medigus Ltd.)		$ 296,845	231				297,076
Issuance of common shares, pre-funded warrants and warrants		$ 1,455,832					1,455,832
Issuance of common shares, pre-funded warrants and warrants (in Shares)	[1]	150,191
Issuance of common shares upon vesting of restricted stock units		$ 150,071		(150,071)
Issuance of common shares upon vesting of restricted stock units (in Shares)	[1]	561
Common shares for services				40,372			40,372
Share-based compensation				199,567			199,567
Balance at Apr. 30, 2023		$ 14,635,719	459,341	2,324,171	(21,250)	(14,123,077)	3,274,904
Balance (in Shares) at Apr. 30, 2023	[1]	233,206
Balance at Oct. 31, 2023		$ 17,131,223	459,341	2,182,221	(21,250)	(18,768,063)	983,472
Balance (in Shares) at Oct. 31, 2023	[1]	607,337
Net loss for the period						(2,276,017)	(2,276,017)
Issuance of common shares, pre-funded warrants and warrants		$ 1,459,815					1,459,815
Issuance of common shares, pre-funded warrants and warrants (in Shares)	[1]	1,500,000
Exercise of warrants		$ 4,154,389					4,154,389
Exercise of warrants (in Shares)	[1]	1,194,102
Issuance of common shares upon vesting of restricted stock units		$ 11,935		(11,935)
Issuance of common shares upon vesting of restricted stock units (in Shares)	[1]	9,000
Share-based compensation		$ 185		323,910			324,095
Share-based compensation (in Shares)		89
Balance at Apr. 30, 2024		$ 22,757,547	$ 459,341	$ 2,494,196	$ (21,250)	$ (21,044,080)	$ 4,645,754
Balance (in Shares) at Apr. 30, 2024	[1]	3,310,528
[1] On November 28, 2023, the Company effected a 1-for-30 reverse split of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share then held. All share amounts have been retroactively adjusted for all periods presented.

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Operating activities
Net loss	$ (2,276,017)	$ (3,975,851)
Adjustments for:
Amortization of intangible assets	5,462	4,975
Amortization of right-of-use asset	17,804	26,789
Interest on lease liability	1,629	2,682
Exchange rate differences	(8,980)	(77)
Share issuance costs allocated to derivate warrant liability	115,046
Depreciation of property and equipment	1,103	3,813
Changes in fair value of derivative warrant liability	(560,145)	360,557
Share-based compensation	324,095	246,446
Unrealized (gain) loss on short-term investment	(415,826)	58,749
Realized loss on short-term investment	423,438
Tax expenses	71,237	12,650
Changes in working capital:
Decrease (increase) in other receivables	72,078	(100,197)
Increase in prepaid expenses	(170,422)	(249,028)
Decrease in accounts payable and accrued liabilities	(260,480)	(405,984)
Increase (decrease) in due to / from related parties	5,205	(158,173)
Net cash used in operating activities	(2,654,773)	(4,172,649)
Investing activities
Proceeds from sale of short-term investment	78,500
Net cash generated in investing activities	78,500
Financing activities
Proceeds from issuance of common shares and warrants, net of issuance costs (Note 6c (iii))	1,824,773	9,321,796
Proceeds received from exercise of warrants (Notes 6c (ii,v))	3,655,950
Repayment of lease liabilities	(19,087)	(30,984)
Net cash provided by financing activities	5,461,636	9,290,812
Effect of foreign exchange rate changes on cash and cash equivalents	(7,175)	(1,233)
Net increase in cash and cash equivalents	2,878,188	5,116,930
Cash and cash equivalents at beginning of period	5,427,739	128,777
Cash and cash equivalents at end of period	8,305,927	5,245,707
Supplementary disclosure of cash flow information:
Cash received for interest	120,612	26,663
Cash paid for taxes	192,825
Non-cash financing and investing activities
Derivative liability converted to equity		290,569
Right of use assets obtained in exchange for lease liabilities	107,827
Early termination of office lease (Note 4c)	$ (88,562)

Nature of Operations and Going

Nature of Operations and Going Concern	6 Months Ended
	Apr. 30, 2024
Nature of Operations and Going Concern [Abstract]
Nature of Operations and Going Concern	1. Nature of Operations and Going Concern a. Clearmind Medicine Inc. (the “Company”) was incorporated in the province of British Columbia on July 18, 2017. The Company is a clinical pharmaceutical company currently engaged in phase I/IIa clinical trials of novel psychedelic medicines that have been developed to solve widespread, yet under-served, health problems. The Company’s head office is located at Suite 101 -1220 West 6 th On November 14, 2022, the Company completed a listing on the Nasdaq Capital Market (“Nasdaq”). The Company trades under the symbol “CMND” on the Nasdaq and on the Frankfurt Stock Exchange, (FSE), under the symbol “CWY”. The Company was listed on the Canadian Securities Exchange (“CSE”) in Toronto until March 14, 2024. Following approval for a voluntary delisting, the Company no longer trades on the CSE but remains a reporting issuer in Canada. On January 16, 2024, the Company completed a registered direct and private placement for aggregate gross proceeds of $2.40 million. See note 6(c)(iii). b. Going concern These condensed interim consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. For the six months ended April 30, 2024, the Company has not generated any revenues and has negative cash flows from operations of $2,654,773. As of April 30, 2024, the Company has an accumulated deficit of $21,044,080. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing through debt or equity. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company’s liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These factors raise substantial doubt on the Company’s ability to continue as a going concern. These condensed interim consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. c. Reverse share split On November 28, 2023, the Company’s Board of Directors (the “Board”) approved a 1-for-30 reverse split of its issued and outstanding common shares, effective as of November 28, 2023, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share then held. All issued and outstanding common shares or instruments convertible into common shares contained in these financial statements have been retroactively adjusted to reflect the reverse share split for all periods presented, unless explicitly stated otherwise.

Material Accounting Policy Info

Material Accounting Policy Information	6 Months Ended
	Apr. 30, 2024
Material Accounting Policy Information [Abstract]
Material Accounting Policy Information	2. Material Accounting Policy Information a. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These condensed interim consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Corp. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”), and are presented in United States dollars, which is the Company’s functional currency. b. Unaudited Interim Financial Information Certain information and footnote disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended October 31, 2023 and the notes thereto (the “2023 Annual Report”). The condensed interim consolidated financial statements have been prepared on the same basis as the 2023 Annual Report. In the opinion of the Company’s management, these condensed interim consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the six months ended April 30, 2024 are not necessarily indicative of the results for the year ending October 31, 2024, or for any future period. As of April 30, 2024, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2023 Annual Report except for the following: Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements—Disclosure of Accounting Policies The Company has adopted the amendments to IAS 1 for the first time in the current year. The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term ‘significant accounting policies’ with ‘material accounting policy information’. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material. c. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Warrant Liability The Company analyses warrants issued to determine whether they meet the classification as liabilities or equity. Derivative warrant liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations. The Company uses a fair valuation specialist to estimate the value of these instruments using the binomial pricing model. The key assumptions used in the models are the expected future volatility in the price of the Company’s shares, the expected life of the warrants and the probability of any future adjustment event. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the end of the reporting period. The Company is aware that material uncertainties related to events or conditions raise substantial doubt upon the Company’s ability to continue as a going concern.

Short-term Investment

Short-term Investment	6 Months Ended
	Apr. 30, 2024
Short-term Investment [Abstract]
Short-term Investment	3. Short-term Investment Pursuant to the Share Exchange Agreement with XYLO TECHNOLOGIES LTD. (formerly Medigus Ltd.) (“XYLO”), on February 14, 2022, the Company received 27,778 ordinary shares of XYLO, the investment cost was $501,938. During the six months ended April 30, 2024, the Company sold all the shares of XYLO, for total proceeds of $78,500 and recorded a net realized loss of $7,612. October 31, Disposals Net realized April 30, XYLO – Shares $ 86,112 $ 78,500 $ (7,612 ) $ – October 31, Additions Unrealized October 31, XYLO – Shares $ 193,750 $ – $ (107,638 ) $ 86,112

Related Party Transactions

Related Party Transactions	6 Months Ended
	Apr. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions a. Compensation to key management personnel (i) The compensation to key management personnel for services they provide to the Company is as follows: Three months Three months ended Six months Six months April 30, April 30, April 30, April 30, 2024 2023 2024 2023 Officers: Consulting fees $ 78,586 $ 87,471 $ 248,274 $ 220,501 Share based compensation 25,854 30,188 41,555 75,380 $ 113,440 $ 117,659 $ 289,829 $ 295,881 Directors: Directors’ fees $ 50,902 $ 41,834 $ 125,525 $ 80,976 Share based compensation 68,669 34,029 85,890 78,124 $ 119,571 $ 75,863 $ 211,415 $ 159,100 (ii) Balances with related parties April 30, October 31, 2024 2023 Amounts owed to officers $ 30,136 $ 29,666 Amounts owed to directors 16,873 12,767 $ 47,009 $ 42,433 b. On March 7, 2022, the Company signed an agreement with SciSparc Ltd (“SciSparc”), pursuant to which the Company and SciSparc agreed to cooperate in conducting a feasibility study using certain molecules developed by each party (the “Cooperation Agreement”). Certain of the Company’s officers and directors currently operate, manage or are engaged as officers and/or directors of SciSparc. In June 2023, the Company entered into a research agreement with the Hebrew University of Jerusalem to evaluate SciSparc’s and the Company’s combination treatment for obesity and metabolic syndrome. To date, the collaboration has resulted in the filing of nine patent applications. To the extent the parties determine to proceed to a commercial cooperation, they may enter into a joint venture by the parties share the economics and rights on a 50%-50% basis. To date, no determination has been made to pursue the joint venture as the development of the project remains at a very early stage. For the three and six months ended April 30, 2024, the Company incurred research and development expenses conducted within the framework of the Cooperation Agreement in the amount of $22,306 and $22,808, respectively (three and six months ended April 30, 2023- $30,863 and $88,493 respectively). As of April 30, 2024, $105,022 is owed to the Company by SciSparc (October 31, 2023- $136,002). c. On December 25, 2023, the Company entered into an agreement with SciSparc for the lease of office space in Tel Aviv, Israel, having a total area of approximately 240 square meters. The Company occupies approximately 120 square meters of the space for its offices. The Company’s base rent was ILS 23,300 per month ($6,500) during the term of the lease. The lease liability was discounted using the Company’s estimated incremental borrowing rate of 10%. On March 31, 2024, the Company and SciSparc decided to terminate the lease agreement prior to the initial term of the lease. As a result, the Company paid early termination fees of approximately $15,000 and paid approximately $3,600 to a broker. The loss upon early termination related to this transaction was recorded as general and administrative expenses within the Condensed Interim Consolidated Statements of Operations and Comprehensive Loss. As of April 30, 2024, the Company and SciSparc were in the process of negotiating the terms of a new lease contract.

Derivative Warrant Liabilities

Derivative Warrant Liabilities	6 Months Ended
	Apr. 30, 2024
Derivative Warrant Liabilities [Abstract]
Derivative warrant liabilities	5. Derivative warrant liabilities a. On April 6, 2023, the Company issued 150,191 warrants in connection with its April 2023 Public Offering (“April 2023 Warrants”). The warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“April 2023 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability and the time of the grant and are revalued at the end of each reporting period. On January 21, 2024, following the January 2024 Public Offering, which included the offering of common shares at a price lower than the exercise price of the April 2023 Warrants, the exercise price of the April 2023 Warrants was reduced to $1.077, and each April 2023 Warrant became exercisable into 9.124 common shares of the Company. During the period between November 29, 2023 and December 5, 2023, 71,520 April 2023 Warrants were exercised into 652,521 common shares. During the period between March 8, 2024 and March 22, 2024, 2,219 April 2023 Warrants were exercised into 20,245 common shares. b. On September 18, 2023, the Company issued 250,000 warrants in connection with its September 2023 Public Offering (“September 2023 Warrants”). The warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“September 2023 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability and the time of the grant and are revalued at the end of each reporting period. On January 21, 2024, following the January 2024 Public Offering, which included the offering of common shares at a price lower than the exercise price of the September 2023 Warrants, the exercise price of the September 2023 Warrants was reduced to $1.077, and each September 2023 Warrant became exercisable into 4.988 common shares of the Company. During the period between November 29, 2023 and December 5, 2023, 82,138 September 2023 Warrants were exercised into 409,667 common shares. During the period between February 23, 2024 and March 22, 2024, 16,334 September 2023 Warrants were exercised into 81,469 common shares. c. On January 16, 2024, the Company issued 1,500,000 warrants with an exercise price of $1.60 per warrant in connection with its January 2024 Public Offering (“January 2024 Warrants”). Each warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“January 2024 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability at the time of the grant and are revalued at the end of each reporting period. On February 23, 2024, 30,200 January 2024 Warrants were exercised into 30,200 common shares. d. During the three and six months ended April 30, 2024, the Company recorded a gain on the revaluation of the total derivative warrant liabilities of $405,002 and $560,145, respectively, in the Condensed Interim Consolidated Statements of Operations and Comprehensive Loss. e. The binomial model was used to measure the derivative warrant liability with the following assumptions: April 30, Share Price $1.19 Exercise Price $1.077-$1.60 Expected life 3.93-4.71 years Risk-free interest rate 4.74-4.80 % Dividend yield 0.00 % Expected volatility 158.07-158.93 % f. The following table presents the changes in the derivative warrant liability during the period: Balance as of November 1, 2022 $ - Issuance of April 2023 Warrants 1,771,208 Issuance of September 2023 Warrants 923,225 Exercise of warrants (574,040 ) Changes in fair value of warrants 2,189,986 Balance as of October 31, 2023 $ 4,310,379 Issuance of January 2024 Warrants 480,004 Exercise of warrants (498,439 ) Changes in fair value of warrants (560,145 ) Balance as of April 30, 2024 $ 3,731,799

Share Capital

Share Capital	6 Months Ended
	Apr. 30, 2024
Share Capital [Abstract]
Share Capital	6. Share Capital a. The Company’s authorized share capital is unlimited common shares without par value share. As of April 30, 2024, the number of common shares issued and outstanding was 3,310,528 (October 31, 2023 – 607,337). b. On November 28, 2023, the Company effected a 1-for-30 share consolidation. All share amounts and instruments convertible into common shares prior to the date of the reverse share split have been retroactively restated for all periods presented. c. Share transactions during the six months ended April 30, 2024: (i) On November 6, 2023, 45 common shares with a fair value of $117 were issued to providers of investor services in payment of services. (ii) Between November 29, 2023 and December 5, 2023, April 2023 Warrants and September 2023 Warrants were exercised into 1,062,188 shares, resulting in gross proceeds of $3,498,032. (iii) On January 16, 2024, the Company completed a registered direct offering and concurrent private placement of (i) 1,468,000 Common Shares, (ii) 32,000 pre-funded warrants to purchase 32,000 Common Shares and (iii) 1,500,000 unregistered common warrants to purchase 1,500,000 Common Shares. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per Common Share and will not expire until exercised in full. The unregistered common warrants have an exercise price of $1.60 per Common Share (after giving effect to adjustments and subject to further adjustments as set forth therein), are immediately exercisable, and expire five years from the date of issuance. These warrants include a cashless exercise provision and repricing provisions, under certain circumstances (“the January 2024 Offering”). The gross proceeds from the January 2024 Offering were approximately $2.4 million before deducting estimated offering expenses. Net proceeds from the offering were $1,824,773. On January 17, 2024, the pre-funded warrants were exercised. (iv) On February 19, 2024, 44 common shares with a fair value of $68 were issued to providers of investor services in payment of services. (v) During the period between February 23, 2024 and March 2, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants were exercised into 131,914 shares, for gross proceeds of $157,918. (vi) On April 3, 2024, 9,000 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $11,935 at the time of issuance. d. Share transactions during the six months ended April 30, 2023: (i) On November 14, 2022, the Company completed an underwritten public offering of 38,462 common shares at a price to the public of $195.00 per share, for aggregate gross proceeds of $7.5 million, prior to deducting underwriting discounts and offering expenses. The offering closed on November 17, 2022. Net proceeds from the offering were $6,363,906. In addition, the Company granted Aegis Capital Corp. (“Aegis”), who acted as the underwriters for the deal, a 45-day option to purchase up to 5,769 additional common shares, equal to 15% of the number of common shares sold in the offering solely to cover over-allotments, if any (“Over-Allotment”). The public purchase price per additional common share would have been $195.00 per share. The Over-Allotment was not exercised. Aegis received 1,923 underwriter warrants, (the “Underwriter Warrants”) each such Underwriter Warrant entitling the agents to receive one common share upon payment of $243.75 per share, exercisable six months after the commencement of sales of this offering and expiring on a date which is no more than five years after the commencement of sales of the offering. The fair value of the Underwriter Warrants of $337,579 were accounted for as an issuance cost within the share-based payment reserve. The fair value of the Underwriter Warrants was estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 150 % In connection with the offering, the Company’s common shares were approved for listing on the Nasdaq and began trading on the Nasdaq (in addition to the CSE) under the symbol “CMND” on November 15, 2022. Following the public offering and pursuant to the XYLO SPA, XYLO was entitled to receive 1,494 common shares and 75 warrants pursuant to an anti-dilution clause included in the agreement signed between the Company and XYLO on June 29, 2022. The anti-dilution feature was recorded as a derivative liability as of October 31, 2022. (ii) On January 16, 2023, 161 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $39,975 at the time of issuance. On February 22, 2023, 400 common shares were issued in respect of fully vested RSU’s that had been fully vested. The RSU’s had a fair value of $110,096 at the time of issuance. (iii) On April 6, 2023, the Company completed an underwritten public offering of 103,249 common shares at a price to the public of $23.40 per share and pre-funded warrants to purchase 46,942 common shares at a price to the public of $23.37 per pre-funded warrant (“Pre-Funded Warrants”), for aggregate gross proceeds of $3.5 million (the “April 2023 Public Offering”). The Pre-Funded Warrants were exercisable at $0.03 into one common share, and all the Pre-Funded Warrants were exercised by April 30, 2023. In addition, each April 2023 Public Offering shareholder and each Pre-Funded Warrant holder received a common warrant, which was immediately exercisable, will expire five years from the date of issuance and have an exercise price of $23.40 per common share (“April 2023 Public Offering Warrant”). The April 2023 Public Offering warrants include a cashless exercise provision and repricing provisions under certain circumstances, that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. On September 24, 2023, as a result of the September 2023 Public Offering, which included the offering of common shares at a price lower than the exercise price of the April 2023 Warrants, the exercise price of these warrants was reduced to $5.124, and each April 2023 Warrant is convertible into 4.6 common shares of the Company. Net proceeds from the offering were $2,936,079.

Warrants

Warrants	6 Months Ended
	Apr. 30, 2024
Warrants [Abstract]
Warrants	7. Warrants The following table summarizes the changes in the Company’s warrants: Number of Weighted Balance, October 31, 2022 19,763 576.66 Issuance of underwriter warrants 1,923 243.75 Issuance of April 2023 warrants (*) 150,191 5.124 Issuance of September 2023 warrants (**) 250,000 9.00 Issuance of XYLO warrants 75 1,297.67 Expiration of warrants (11,430 ) 922.98 Exercise of warrants (26,153 ) 5.124 Balance, October 31, 2023 384,369 $ 7.90 Number of shares to be issued from the exercise of warrants 826,781 Balance, October 31, 2023 384,369 $ 7.90 Issuance of January 2024 warrants (Note 5c) 1,500,000 1.60 Exercise of warrants (202,411 ) 3.04 Expiration of warrants (8,333 ) 98.43 Balance, April 30, 2024 1,673,625 $ 1.53 Number of shares to be issued from the exercise of warrants 2,925,075 (*) These warrants convert into 697,520 shares. (**) These warrants convert into 755,757 shares. As of April 30, 2024, the following warrants were outstanding: Number of Number of shares Exercise price Exercise price (USD) Expiry date 1,923 1,923 C$ 335.06 $ 243.75 November 17, 2027 50,299 697,520 $ 1.077 $ 1.077 April 5, 2028 75 75 C$ 1,800 $ 1,309.47 November 23, 2024 151,528 755,757 $ 1.077 $ 1.077 September 17, 2028 1,469,800 1,469,800 $ 1.60 $ 1.60 January 15, 2025 1,673,625 2,925,075

Stock Options

Stock Options	6 Months Ended
	Apr. 30, 2024
Stock Options [Abstract]
Stock Options	8. Stock Options (a) On November 14, 2023, the shareholders of the Company approved the Omnibus Equity Incentive Plan, or the Omnibus Plan. Pursuant to the Omnibus Plan, the Company is authorized to grant options or restricted share units (“RSUs) to officers, directors, employees and consultants enabling them to acquire, together with” Options”, “Awards” or “Stock Options” as defined, up to 20% of our issued and outstanding Common Shares (after taking into account existing awards from the Company’s 2021 stock option plan). The Awards can be granted for a maximum of 10 years and vest as determined by the Board. The maximum number of common shares reserved for issuance in any 12-month period to a related party consultant may not exceed 5% of the issued and outstanding common shares at the date of the grant (and may not exceed 15% in total, to all related parties). The maximum number of common shares reserved for issuance in any 12-month period to any investor relations service provider may not exceed 2% of the issued and outstanding common shares at the date of the grant. (b) The following table summarizes the changes in the Company’s stock options for the periods ended April 30, 2024 and October 31, 2023: Number of options Weighted average exercise price (C$) Weighted average exercise price (USD$) Outstanding, October 31, 2022 5,254 C$ 613.5 $ 450.64 Granted 334 442.22 318.81 Outstanding, October 31, 2023 5,588 C$ 603.12 $ 434.81 Expired (67 ) 720.00 533.14 Outstanding, April 30, 2024 5,521 C$ 601.70 $ 437.73 Exercisable, April 30, 2024 4,803 C$ 604.01 $ 439.41 (c) Additional information regarding stock options outstanding as of April 30, 2024, is as follows: Outstanding Exercisable Number of Weighted Weighted Weighted Number of Weighted Weighted 533 2.07 C$ 166.50 $ 121.13 489 C$ 166.50 $ 121.13 978 7.76 504.00 366.65 795 504.00 366.65 1,166 2.07 675.00 491.05 1,110 675.00 491.05 200 5.00 702.00 510.69 174 702.00 510.69 133 2.39 747.00 543.43 133 747.00 543.43 422 7.61 612.00 445.22 422 612.00 445.22 1,044 7.76 720.00 523.79 783 720.00 523.79 667 2.17 756.00 549.98 611 756.00 549.98 111 7.61 900.00 654.74 93 900.00 654.74 61 9.07 315.00 229.16 46 315.00 229.16 156 9.16 504.00 366.65 130 504.00 366.65 50 9.19 32.17 23.40 17 32.17 23.40 5,521 5.16 C$ 601.70 $ 437.73 4,803 C$ 604.01 $ 439.41 The fair value for stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: six months six months Risk-free interest rate 3.89 % 3.89 % Expected life (in years) 5.11 5.13 Expected volatility 150.79%-161.87 % 113%-118 % d. The portion of the total fair value of stock options expensed during the three and six months ended April 30, 2024, were $23,292 and $56,870, respectively (2023 - $22,804 and $121,935, respectively) which was recorded as share-based compensation expense.

Restricted Share Units

Restricted Share Units	6 Months Ended
	Apr. 30, 2024
Restricted Share Units [Abstract]
Restricted Share Units	9. Restricted Share Units The following table summarizes the continuity of RSUs: Number of Weighted Weighted Balance, October 31, 2022 – $ – $ – Granted 2,200 55.97 41.46 Vested (2,200 ) 55.97 41.46 Balance, October 31, 2023 – $ – $ – Granted (i) 437,765 1.78 1.29 Vested (200,784 ) 1.80 1.33 Balance, April 30, 2024 236,981 $ 1.76 $ 1.28 (i) During the six months ended April 30, 2024, the Company issued 437,765 RSU’s to consultants, directors and officers. 200,784 RSU’s vested with a fair value of $267,346 (2023-$77,632).

Financial Instruments and Risk

Financial Instruments and Risk Management	6 Months Ended
	Apr. 30, 2024
Financial Instruments and Risk Management [Abstract]
Financial Instruments and Risk Management	10. Financial Instruments and Risk Management a. Assets and liabilities measured at fair value on a recurring basis were presented in the Company’s statement of financial position as of April 30, 2024, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Derivative warrants liability $ – $ – $ 3,731,799 $ 3,731,799 Assets and liabilities measured at fair value on a recurring basis were presented in the Company’s statement of financial position as of October 31, 2023, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 86,112 $ – $ – $ 86,112 Derivative warrants liability – – 4,310,379 4,310,379 The fair value of other assets and liabilities, which include cash, amounts receivable, accounts payable and accrued liabilities, and amounts due to related parties, approximate their carrying values due to the relatively short-term maturity of these instruments. b. Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure. c. Foreign Exchange Rate Risk Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities are denominated in a foreign currency. The Company’s subsidiary operates in Israel and has certain monetary financial instruments denominated in New Israeli Shekel and CAD. The Company has not entered into foreign exchange rate contracts to mitigate this risk. The following table indicates the impact of foreign currency exchange risk on net working capital as of April 30, 2024. The table below also provides a sensitivity analysis of a 10% strengthening of the foreign currency against functional currencies identified which would have increased (decreased) the Company’s net loss by the amounts shown in the table below. A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of April 30, 2024. Cash and cash equivalents $ 238,379 Other receivables 49,369 Accounts payable and accrued liabilities (129,877 ) Due to related parties (37,009 ) Total foreign currency financial assets and liabilities $ 120,862 Impact of a 10% strengthening or weakening of foreign exchange rate $ 12,086 d. Interest Rate Risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk as it does not have any liabilities with variable rates. e. Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s objective to managing liquidity risk is to ensure that it has sufficient liquidity available to meet its liabilities when due. The Company relies on raising debt or equity financing in a timely manner. The following amounts are the contractual maturities of financial liabilities as of April 30, 2024 and October 31, 2023: April 30, 2024 Total Within Within Accounts payable and accrued liabilities $ 421,156 $ 421,156 $ – Due to related parties 47,009 47,009 – $ 468,165 $ 468,165 $ – October 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 617,004 $ 617,004 $ – Due to related parties 42,433 42,433 – $ 659,437 $ 659,437 $ –

Capital Management

Capital Management	6 Months Ended
	Apr. 30, 2024
Capital Management [Abstract]
Capital Management	11. Capital Management The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of cash and equity comprised of issued share capital, RSU reserve, warrants reserve, and options reserve. The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board, will balance its overall capital structure through new share issuances or by undertaking other activities as deemed appropriate under the specific circumstances. The Company is not subject to externally imposed capital requirements and the Company’s overall strategy with respect to capital risk management remains unchanged from the six months ended April 30, 2024.

Segmented Information

Segmented Information	6 Months Ended
	Apr. 30, 2024
Segmented Information [Abstract]
Segmented Information	12. Segmented Information As of April 30, 2024, the Company has one operating segment, being the research and development of novel psychedelic medicine, which takes place primarily in Israel.

Commitments

Commitments	6 Months Ended
	Apr. 30, 2024
Commitments [Abstract]
Commitments	13. Commitments a. On January 15, 2024, the Company signed a long-term licensing agreement with the research & development company of Bar-Ilan University (“BIRAD”), a leading Israeli research center. The licensing agreement refers to the Company’s dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving. Under this agreement, the Company received a worldwide exclusive license and will pay BIRAD certain milestone payments upon commerciality of the product and royalties of 2.5% for a period of 15 years following the first commercial sale. b. On March 19, 2024, the Company signed an exclusive patent licensing agreement with Yissum research development company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University. The Company will pay Yissum, royalties of 3% on sales. In addition, the Company will pay an annual license fee of $25,000 for seven years, after which the license fee will increase to $35,000 for three years, and $50,000 for every year thereafter. Finally, the Company will pay Yissum $400,000 upon the first patient enrolled in a Phase III Clinical Trial and $600,000 upon first commercial sale in the US or EU. c. On Marh 30, 2024, the Company signed an exclusive licensing agreement with Yissum. Under the terms of the agreement, Clearmind receives exclusive worldwide rights to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the company’s innovative portfolio in addiction and mental health treatments. The Company will pay Yissum royalties of 3% on sales. In addition, the Company will pay an annual license fee of $25,000 for seven years, after which the license fee will increase to $35,000 for three years, and $50,000 for every year thereafter. Finally, the Company will pay Yissum $400,000 upon the first patient enrolled in a Phase III Clinical Trial and $600,000 upon first commercial sale in the US or EU. d. Respect to the Company's lease commitment, refer to Note 4c.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Apr. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These condensed interim consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Corp. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”), and are presented in United States dollars, which is the Company’s functional currency.
Unaudited Interim Financial Information	b. Unaudited Interim Financial Information Certain information and footnote disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended October 31, 2023 and the notes thereto (the “2023 Annual Report”). The condensed interim consolidated financial statements have been prepared on the same basis as the 2023 Annual Report. In the opinion of the Company’s management, these condensed interim consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the six months ended April 30, 2024 are not necessarily indicative of the results for the year ending October 31, 2024, or for any future period. As of April 30, 2024, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2023 Annual Report except for the following: Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements—Disclosure of Accounting Policies The Company has adopted the amendments to IAS 1 for the first time in the current year. The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term ‘significant accounting policies’ with ‘material accounting policy information’. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material.
Significant Accounting Estimates and Judgments	c. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Warrant Liability The Company analyses warrants issued to determine whether they meet the classification as liabilities or equity. Derivative warrant liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations. The Company uses a fair valuation specialist to estimate the value of these instruments using the binomial pricing model. The key assumptions used in the models are the expected future volatility in the price of the Company’s shares, the expected life of the warrants and the probability of any future adjustment event. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the end of the reporting period. The Company is aware that material uncertainties related to events or conditions raise substantial doubt upon the Company’s ability to continue as a going concern.

Short-term Investment (Tables)

Short-term Investment (Tables)	6 Months Ended
	Apr. 30, 2024
Short-term Investment [Abstract]
Schedule of Ordinary Shares of Medigus	During the six months ended April 30, 2024, the Company sold all the shares of XYLO, for total proceeds of $78,500 and recorded a net realized loss of $7,612. October 31, Disposals Net realized April 30, XYLO – Shares $ 86,112 $ 78,500 $ (7,612 ) $ – October 31, Additions Unrealized October 31, XYLO – Shares $ 193,750 $ – $ (107,638 ) $ 86,112

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Apr. 30, 2024
Related Party Transactions [Abstract]
Schedule of Key Management Personnel for Employment Services	The compensation to key management personnel for services they provide to the Company is as follows: Three months Three months ended Six months Six months April 30, April 30, April 30, April 30, 2024 2023 2024 2023 Officers: Consulting fees $ 78,586 $ 87,471 $ 248,274 $ 220,501 Share based compensation 25,854 30,188 41,555 75,380 $ 113,440 $ 117,659 $ 289,829 $ 295,881 Directors: Directors’ fees $ 50,902 $ 41,834 $ 125,525 $ 80,976 Share based compensation 68,669 34,029 85,890 78,124 $ 119,571 $ 75,863 $ 211,415 $ 159,100
Schedule of Balances with Related Parties	Balances with related parties April 30, October 31, 2024 2023 Amounts owed to officers $ 30,136 $ 29,666 Amounts owed to directors 16,873 12,767 $ 47,009 $ 42,433

Derivative Warrant Liabilities

Derivative Warrant Liabilities (Tables)	6 Months Ended
	Apr. 30, 2024
Derivative Warrant Liabilities [Abstract]
Schedule of Binomial Model was used to Measure the Derivative Warrant Liability	The binomial model was used to measure the derivative warrant liability with the following assumptions: April 30, Share Price $1.19 Exercise Price $1.077-$1.60 Expected life 3.93-4.71 years Risk-free interest rate 4.74-4.80 % Dividend yield 0.00 % Expected volatility 158.07-158.93 %
Schedule of Changes in the Warrants Liability	The following table presents the changes in the derivative warrant liability during the period: Balance as of November 1, 2022 $ - Issuance of April 2023 Warrants 1,771,208 Issuance of September 2023 Warrants 923,225 Exercise of warrants (574,040 ) Changes in fair value of warrants 2,189,986 Balance as of October 31, 2023 $ 4,310,379 Issuance of January 2024 Warrants 480,004 Exercise of warrants (498,439 ) Changes in fair value of warrants (560,145 ) Balance as of April 30, 2024 $ 3,731,799

Share Capital (Tables)

Share Capital (Tables)	6 Months Ended
	Apr. 30, 2024
Share Capital [Abstract]
Schedule of the Fair Value of Underwriters Warrants	The fair value of the Underwriter Warrants was estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 150 %

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Apr. 30, 2024
Warrants [Abstract]
Schedule of Warrants	The following table summarizes the changes in the Company’s warrants: Number of Weighted Balance, October 31, 2022 19,763 576.66 Issuance of underwriter warrants 1,923 243.75 Issuance of April 2023 warrants (*) 150,191 5.124 Issuance of September 2023 warrants (**) 250,000 9.00 Issuance of XYLO warrants 75 1,297.67 Expiration of warrants (11,430 ) 922.98 Exercise of warrants (26,153 ) 5.124 Balance, October 31, 2023 384,369 $ 7.90 Number of shares to be issued from the exercise of warrants 826,781 Balance, October 31, 2023 384,369 $ 7.90 Issuance of January 2024 warrants (Note 5c) 1,500,000 1.60 Exercise of warrants (202,411 ) 3.04 Expiration of warrants (8,333 ) 98.43 Balance, April 30, 2024 1,673,625 $ 1.53 Number of shares to be issued from the exercise of warrants 2,925,075 (*) These warrants convert into 697,520 shares. (**) These warrants convert into 755,757 shares.
Schedule of Warrants Outstanding	As of April 30, 2024, the following warrants were outstanding: Number of Number of shares Exercise price Exercise price (USD) Expiry date 1,923 1,923 C$ 335.06 $ 243.75 November 17, 2027 50,299 697,520 $ 1.077 $ 1.077 April 5, 2028 75 75 C$ 1,800 $ 1,309.47 November 23, 2024 151,528 755,757 $ 1.077 $ 1.077 September 17, 2028 1,469,800 1,469,800 $ 1.60 $ 1.60 January 15, 2025 1,673,625 2,925,075

Stock Options (Tables)

Stock Options (Tables)	6 Months Ended
	Apr. 30, 2024
Stock Options [Abstract]
Schedule of Changes in Stock Options	The following table summarizes the changes in the Company’s stock options for the periods ended April 30, 2024 and October 31, 2023: Number of options Weighted average exercise price (C$) Weighted average exercise price (USD$) Outstanding, October 31, 2022 5,254 C$ 613.5 $ 450.64 Granted 334 442.22 318.81 Outstanding, October 31, 2023 5,588 C$ 603.12 $ 434.81 Expired (67 ) 720.00 533.14 Outstanding, April 30, 2024 5,521 C$ 601.70 $ 437.73 Exercisable, April 30, 2024 4,803 C$ 604.01 $ 439.41
Schedule of Additional Information Regarding Stock Options Outstanding	Additional information regarding stock options outstanding as of April 30, 2024, is as follows Outstanding Exercisable Number of Weighted Weighted Weighted Number of Weighted Weighted 533 2.07 C$ 166.50 $ 121.13 489 C$ 166.50 $ 121.13 978 7.76 504.00 366.65 795 504.00 366.65 1,166 2.07 675.00 491.05 1,110 675.00 491.05 200 5.00 702.00 510.69 174 702.00 510.69 133 2.39 747.00 543.43 133 747.00 543.43 422 7.61 612.00 445.22 422 612.00 445.22 1,044 7.76 720.00 523.79 783 720.00 523.79 667 2.17 756.00 549.98 611 756.00 549.98 111 7.61 900.00 654.74 93 900.00 654.74 61 9.07 315.00 229.16 46 315.00 229.16 156 9.16 504.00 366.65 130 504.00 366.65 50 9.19 32.17 23.40 17 32.17 23.40 5,521 5.16 C$ 601.70 $ 437.73 4,803 C$ 604.01 $ 439.41
Schedule of Fair Value of Stock Options	The fair value for stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: six months six months Risk-free interest rate 3.89 % 3.89 % Expected life (in years) 5.11 5.13 Expected volatility 150.79%-161.87 % 113%-118 %

Restricted Share Units (Tables)

Restricted Share Units (Tables)	6 Months Ended
	Apr. 30, 2024
Restricted Share Units [Abstract]
Schedule of Changes in RSUs	The following table summarizes the continuity of RSUs: Number of Weighted Weighted Balance, October 31, 2022 – $ – $ – Granted 2,200 55.97 41.46 Vested (2,200 ) 55.97 41.46 Balance, October 31, 2023 – $ – $ – Granted (i) 437,765 1.78 1.29 Vested (200,784 ) 1.80 1.33 Balance, April 30, 2024 236,981 $ 1.76 $ 1.28 (i) During the six months ended April 30, 2024, the Company issued 437,765 RSU’s to consultants, directors and officers. 200,784 RSU’s vested with a fair value of $267,346 (2023-$77,632).

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	6 Months Ended
	Apr. 30, 2024
Financial Instruments and Risk Management [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value	Assets and liabilities measured at fair value on a recurring basis were presented in the Company’s statement of financial position as of April 30, 2024, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Derivative warrants liability $ – $ – $ 3,731,799 $ 3,731,799 Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 86,112 $ – $ – $ 86,112 Derivative warrants liability – – 4,310,379 4,310,379
Schedule of Foreign Currency Exchange Risk on Net Working Capital	A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of April 30, 2024. Cash and cash equivalents $ 238,379 Other receivables 49,369 Accounts payable and accrued liabilities (129,877 ) Due to related parties (37,009 ) Total foreign currency financial assets and liabilities $ 120,862 Impact of a 10% strengthening or weakening of foreign exchange rate $ 12,086
Schedule of Contractual Maturities of Financial Liabilities	The following amounts are the contractual maturities of financial liabilities as of April 30, 2024 and October 31, 2023: April 30, 2024 Total Within Within Accounts payable and accrued liabilities $ 421,156 $ 421,156 $ – Due to related parties 47,009 47,009 – $ 468,165 $ 468,165 $ – October 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 617,004 $ 617,004 $ – Due to related parties 42,433 42,433 – $ 659,437 $ 659,437 $ –

Nature of Operations and Goin_2

Nature of Operations and Going Concern (Details) - USD ($)					6 Months Ended
	Jan. 16, 2024	Nov. 28, 2023	Apr. 06, 2023	Nov. 14, 2022	Apr. 30, 2024	Apr. 30, 2023	Oct. 31, 2023
Nature of Operations and Going Concern [Line Items]
Incorporation date					Jul. 18, 2017
Aggregate gross proceeds	$ 2,400,000		$ 3,500,000	$ 7,500,000
Cash flow from operations					$ (2,654,773)	$ (4,172,649)
Accumulated deficit					(21,044,080)		$ (18,768,063)
Price per share (in Dollars per share)		$ 0.0333
Reverse stock split, description		1-for-30 reverse split
Going Concern [Member]
Nature of Operations and Going Concern [Line Items]
Cash flow from operations					2,654,773
Accumulated deficit					$ 21,044,080

Material Accounting Policy In_2

Material Accounting Policy Information (Details)	6 Months Ended
	Apr. 30, 2024
Material Accounting Policy Information [Abstract]
Ownership percentage	100%

Short-term Investment (Details)

Short-term Investment (Details) - USD ($)		6 Months Ended
	Feb. 14, 2022	Apr. 30, 2024	Apr. 03, 2024	Nov. 06, 2023	Feb. 22, 2023	Feb. 19, 2023	Jan. 16, 2023
Short-term Investment [Line Items]
Number of shares issued (in Shares)			9,000	45	400	44	161
Total proceeds		$ 78,500
Net realized loss		$ (7,612)
Medigus Ltd [Member]
Short-term Investment [Line Items]
Investment cost	$ 501,938
Ordinary shares [member] | Medigus Ltd [Member]
Short-term Investment [Line Items]
Number of shares issued (in Shares)	27,778

Short-term Investment (Detail_2

Short-term Investment (Details) - Schedule of Ordinary Shares of Medigus - Medigus Ltd [Member] - USD ($)	6 Months Ended	12 Months Ended
	Apr. 30, 2024	Oct. 31, 2023
Schedule of Fair Value of Common Shares [Line Items]
Beginning shares	$ 86,112	$ 193,750
Additions / Disposals	78,500
Unrealized gain	(7,612)	(107,638)
Ending shares		$ 86,112

Related Party Transactions (Det

Related Party Transactions (Details)			3 Months Ended		6 Months Ended
	Dec. 25, 2023 USD ($)	Dec. 25, 2023 ILS (₪)	Apr. 30, 2024 USD ($)	Apr. 30, 2023 USD ($)	Apr. 30, 2024 USD ($)	Apr. 30, 2023 USD ($)	Oct. 31, 2023 USD ($)
Related Party Transactions [Line Items]
Research and development expenses			$ 322,956	$ 317,572	$ 550,434	$ 905,202
Owed to the company			105,022		105,022		$ 136,002
Rent expense	$ 6,500	₪ 23,300
Borrowing rate	10%	10%
Termination fees					15,000
Fees to broker					3,600
SciSparc Ltd [Member]
Related Party Transactions [Line Items]
Research and development expenses			22,306	$ 30,863	22,808	$ 88,493
Owed to the company			$ 105,022		$ 105,022		$ 136,002

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Key Management Personnel for Employment Services - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Officers [Member]
Schedule of Key Management Personnel for Employment Services [Line Items]
Consulting and Directors’ fees	$ 78,586	$ 87,471	$ 248,274	$ 220,501
Share based compensation	25,854	30,188	41,555	75,380
key management personnel compensation	113,440	117,659	289,829	295,881
Directors [Member]
Schedule of Key Management Personnel for Employment Services [Line Items]
Consulting and Directors’ fees	50,902	41,834	125,525	80,976
Share based compensation	68,669	34,029	85,890	78,124
key management personnel compensation	$ 119,571	$ 75,863	$ 211,415	$ 159,100

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of Balances with Related Parties - USD ($)	Apr. 30, 2024	Oct. 31, 2023
Schedule of Balances with Related Parties [Line Items]
Balances with related parties	$ 47,009	$ 42,433
Amounts Owed to Officers [Member]
Schedule of Balances with Related Parties [Line Items]
Balances with related parties	30,136	29,666
Amounts Owed to Directors [Member]
Schedule of Balances with Related Parties [Line Items]
Balances with related parties	$ 16,873	$ 12,767

Derivative Warrant Liabilitie_2

Derivative Warrant Liabilities (Details) - USD ($)

1 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

15 Months Ended

Mar. 22, 2024

Feb. 23, 2024

Jan. 21, 2024

Jan. 16, 2024

Dec. 05, 2023

Nov. 29, 2023

Sep. 24, 2023

Mar. 22, 2024

Dec. 05, 2023

Apr. 30, 2024

Apr. 30, 2023

Apr. 30, 2024

Apr. 30, 2023

Oct. 31, 2023

Apr. 30, 2024

Apr. 03, 2024

Nov. 06, 2023

Sep. 18, 2023

Apr. 06, 2023

Feb. 22, 2023

Feb. 19, 2023

Jan. 16, 2023

Derivative Warrant Liabilities [Line Items]

Warrants issued

9,000

45

400

44

161

Convertible common shares

4.6

Gain on revaluation total derivative warrants liabilities (in Dollars)

$ 405,002

$ (360,557)

$ 560,145

$ (360,557)

$ 2,189,986

$ 405,002

April 2023 Warrants [Member]

Derivative Warrant Liabilities [Line Items]

Warrants issued

150,191

Warrant price per share (in Dollars per share)

$ 1.077

Convertible common shares

20,245

9.124

652,521

Number of warrants shares

2,219

71,520

September 2023 Warrants [Member]

Derivative Warrant Liabilities [Line Items]

Warrants issued

250,000

Warrant price per share (in Dollars per share)

$ 1.077

Convertible common shares

4.988

Number of warrants shares

82,138

16,334

Warrants exercised common share

81,469

409,667

January 2024 Warrants [Member]

Derivative Warrant Liabilities [Line Items]

Warrants issued

1,500,000

Warrant price per share (in Dollars per share)

$ 1.6

Number of warrants shares

30,200

Warrants exercised common share

30,200

Gain on revaluation total derivative warrants liabilities (in Dollars)

$ (560,145)

Derivative Warrant Liabilitie_3

Derivative Warrant Liabilities (Details) - Schedule of Binomial Model was used to Measure the Derivative Warrant Liability	6 Months Ended
	Apr. 30, 2024 Duration $ / shares
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Share Price (in Dollars per share)	$ 1.19
Dividend yield	0%
Bottom of Range [Member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Exercise Price (in Dollars per share)	$ 1.077
Expected life (in Duration) | Duration	3.93
Risk-free interest rate	4.74%
Expected volatility	158.07%
Top of Range [Member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Exercise Price (in Dollars per share)	$ 1.6
Expected life (in Duration) | Duration	4.71
Risk-free interest rate	4.80%
Expected volatility	158.93%

Derivative Warrant Liabilitie_4

Derivative Warrant Liabilities (Details) - Schedule of Changes in the Warrants Liability - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended	15 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023	Oct. 31, 2023	Apr. 30, 2024
Schedule of Changes in the Warrants Liability [Line Items]
Balance at beginning			$ 4,310,379
Exercise of warrants					(574,040)
Changes in fair value of warrants	$ 405,002	$ (360,557)	560,145	$ (360,557)	2,189,986	$ 405,002
Balance at ending	3,731,799		3,731,799		4,310,379	3,731,799
April 2023 Warrants [Member]
Schedule of Changes in the Warrants Liability [Line Items]
Issuance of Warrants					1,771,208
September 2023 Warrants [Member]
Schedule of Changes in the Warrants Liability [Line Items]
Issuance of Warrants					$ 923,225
January 2024 Warrants [Member]
Schedule of Changes in the Warrants Liability [Line Items]
Issuance of Warrants			480,004
Exercise of warrants			(498,439)
Changes in fair value of warrants			(560,145)
Balance at ending	$ 3,731,799		$ 3,731,799			$ 3,731,799

Share Capital (Details)

Share Capital (Details)											6 Months Ended
	Apr. 03, 2024 USD ($) shares	Jan. 16, 2024 USD ($) $ / shares shares	Dec. 05, 2023 USD ($)	Nov. 06, 2023 USD ($) shares	Sep. 24, 2023 $ / shares shares	Apr. 06, 2023 USD ($) $ / shares shares	Feb. 22, 2023 USD ($) shares	Feb. 19, 2023 USD ($) shares	Jan. 16, 2023 USD ($) shares	Nov. 14, 2022 USD ($) $ / shares shares	Apr. 30, 2024 USD ($) $ / shares shares	Jun. 29, 2024 shares	Oct. 31, 2023 shares
Share Capital [Line Items]
Number of shares issued	9,000			45			400	44	161
Description of reverse share split											On November 28, 2023, the Company effected a 1-for-30 share consolidation. All share amounts and instruments convertible into common shares prior to the date of the reverse share split have been retroactively restated for all periods presented.   c. Share transactions during the six months ended April 30, 2024: (i)On November 6, 2023, 45 common shares with a fair value of $117 were issued to providers of investor services in payment of services.   (ii) Between November 29, 2023 and December 5, 2023, April 2023 Warrants and September 2023 Warrants were exercised into 1,062,188 shares, resulting in gross proceeds of $3,498,032.   (iii) On January 16, 2024, the Company completed a registered direct offering and concurrent private placement of (i) 1,468,000 Common Shares, (ii) 32,000 pre-funded warrants to purchase 32,000 Common Shares and (iii) 1,500,000 unregistered common warrants to purchase 1,500,000 Common Shares. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per Common Share and will not expire until exercised in full. The unregistered common warrants have an exercise price of $1.60 per Common Share (after giving effect to adjustments and subject to further adjustments as set forth therein), are immediately exercisable, and expire five years from the date of issuance. These warrants include a cashless exercise provision and repricing provisions, under certain circumstances (“the January 2024 Offering”). The gross proceeds from the January 2024 Offering were approximately $2.4 million before deducting estimated offering expenses. Net proceeds from the offering were $1,824,773. On January 17, 2024, the pre-funded warrants were exercised. (iv)On February 19, 2024, 44 common shares with a fair value of $68 were issued to providers of investor services in payment of services. (v)During the period between February 23, 2024 and March 2, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants were exercised into 131,914 shares, for gross proceeds of $157,918. (vi)On April 3, 2024, 9,000 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $11,935 at the time of issuance.   d. Share transactions during the six months ended April 30, 2023:   (i) On November 14, 2022, the Company completed an underwritten public offering of 38,462 common shares at a price to the public of $195.00 per share, for aggregate gross proceeds of $7.5 million, prior to deducting underwriting discounts and offering expenses. The offering closed on November 17, 2022. Net proceeds from the offering were $6,363,906. In addition, the Company granted Aegis Capital Corp. (“Aegis”), who acted as the underwriters for the deal, a 45-day option to purchase up to 5,769 additional common shares, equal to 15% of the number of common shares sold in the offering solely to cover over-allotments, if any (“Over-Allotment”). The public purchase price per additional common share would have been $195.00 per share. The Over-Allotment was not exercised. Aegis received 1,923 underwriter warrants, (the “Underwriter Warrants”) each such Underwriter Warrant entitling the agents to receive one common share upon payment of $243.75 per share, exercisable six months after the commencement of sales of this offering and expiring on a date which is no more than five years after the commencement of sales of the offering. The fair value of the Underwriter Warrants of $337,579 were accounted for as an issuance cost within the share-based payment reserve. The fair value of the Underwriter Warrants was estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate   1.43% Expected life (in years)   5  Expected volatility   150% In connection with the offering, the Company’s common shares were approved for listing on the Nasdaq and began trading on the Nasdaq (in addition to the CSE) under the symbol “CMND” on November 15, 2022.
Common shares fair value (in Dollars) | $				$ 117				$ 68
Exercised shares			1,062,188								131,914
Gross proceeds (in Dollars) | $		$ 2,400,000	$ 3,498,032								$ 157,918
Underwritten public offering		1,468,000				103,249
Warrants purchase						46,942
Purchase common shares		1,500,000
Unregistered common warrants		1,500,000
Expire term		5 years
Net proceeds from the offering (in Dollars) | $		$ 1,824,773									$ 2,936,079
Fair value of RSU (in Dollars) | $	$ 11,935						$ 110,096		$ 39,975
Issuance of common share										38,462
Purchase price per share (in Dollars per share) | $ / shares											$ 195
Aggregate gross proceeds (in Dollars) | $		$ 2,400,000				$ 3,500,000				$ 7,500,000
Additional common shares											5,769
Common shares percentage											15%
Received underwriter warrants											1,923
Fair value of underwriter warrants (in Dollars) | $											$ 337,579
Public per share (in Dollars per share) | $ / shares						$ 23.4
Pre-funded warrants purchased (in Dollars per share) | $ / shares						23.37
Pre-funded warrants were exercisable (in Dollars per share) | $ / shares						0.03
Exercise price per common share (in Dollars per share) | $ / shares						$ 23.4
Exercise price of these warrants was reduced (in Dollars per share) | $ / shares					$ 5.124
Convertible warrant into common shares					4.6
Common Shares [Member]
Share Capital [Line Items]
Number of shares outstanding											3,310,528		607,337
Number of shares issued											3,310,528		607,337
Purchase common shares		32,000
Purchase price per share (in Dollars per share) | $ / shares										$ 195
Net proceeds from offering post (in Dollars) | $										$ 6,363,906
Payment per share (in Dollars per share) | $ / shares											$ 243.75
Medigus SPA [Member]
Share Capital [Line Items]
Number of shares issued												1,494
Warrants [Member]
Share Capital [Line Items]
Exercise price (in Dollars per share) | $ / shares		$ 1.6
Pre-Funded Warrants [Member]
Share Capital [Line Items]
Warrants purchase		32,000
Exercise price (in Dollars per share) | $ / shares		$ 0.0001
April 2023 Public Offering Warrant [Member]
Share Capital [Line Items]
Expire term						5 years
Warrants [Member]
Share Capital [Line Items]
Number of shares issued												75

Share Capital (Details) - Sched

Share Capital (Details) - Schedule of the Fair Value of Underwriters Warrants - Option pricing model [member]	6 Months Ended
	Apr. 30, 2024
Schedule of the Fair Value of Underwriters Warrants [Line Items]
Risk-free interest rate	1.43%
Expected life (in years)	5 years
Expected volatility	150%

Warrants (Details)

Warrants (Details)	6 Months Ended
	Apr. 30, 2024 shares
April 2023 Warrants [Member]
Share Purchase Warrants [Line Items]
Warrants converted into share	697,520
September 2023 Warrant [Member]
Share Purchase Warrants [Line Items]
Warrants converted into share	755,757

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of Warrants		6 Months Ended	12 Months Ended
		Apr. 30, 2024 $ / shares shares	Oct. 31, 2023 $ / shares shares
Schedule of Warrants [Line Items]
Number of warrants, Balance beginning		384,369	19,763
Weighted average exercise price, Balance beginning (in Dollars per share) | $ / shares		$ 7.9	$ 576.66
Number of warrants, Issuance of underwriter warrants			1,923
Weighted average exercise price, Issuance of underwriter warrants			243.75
Number of warrants, Issuance of warrants		1,500,000	150,191	[1]
Weighted average exercise price,Issuance of warrants (in Dollars per share) | $ / shares		$ 1.6	$ 5.124	[1]
Number of warrants, Issuance of warrants	[2]		250,000
Weighted average exercise price, Issuance of warrants (in Dollars per share) | $ / shares	[2]		$ 9
Number of warrants,Issuance of XYLO warrants			75
Weighted average exercise price, Issuance of XYLO warrants			1,297.67
Number of warrants, Expiration of warrants		(8,333)	(11,430)
Weighted average exercise price, Expiration of warrants		98.43	922.98
Number of warrants, Exercise of warrants		(202,411)	(26,153)
Weighted average exercise price, Exercise of warrants (in Dollars per share) | $ / shares		$ 3.04	$ 5.124
Number of warrants, Balance ending		1,673,625	384,369
Weighted average exercise price, Balance ending (in Dollars per share) | $ / shares		$ 1.53	$ 7.9
Number of warrants, Number of shares to be issued from the exercise of warrants		2,925,075
Weighted average exercise price, Number of shares to be issued from the exercise of warrants (in Dollars per share) | $ / shares
Number of warrants, Number of shares to be issued from the exercise of warrants			826,781
[1] These warrants convert into 697,520 shares. These warrants convert into 755,757 shares.

Warrants (Details) - Schedule_2

Warrants (Details) - Schedule of Warrants Outstanding	Apr. 30, 2024 $ / shares shares	Apr. 30, 2024 $ / shares shares
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	1,673,625	1,673,625
Number of shares to be issued from the exercise of warrants	2,925,075	2,925,075
Expiry date November 17, 2027 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	1,923	1,923
Number of shares to be issued from the exercise of warrants	1,923	1,923
Exercise price (in Dollars per share and Dollars per share) | $ / shares	$ 243.75
Expiry date	Nov. 17, 2027
Expiry date November 17, 2027 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price (in Dollars per share and Dollars per share) | $ / shares		$ 335.06
Expiry date April 5, 2028 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	50,299	50,299
Number of shares to be issued from the exercise of warrants	697,520	697,520
Exercise price (in Dollars per share and Dollars per share) | $ / shares	$ 1.077
Expiry date	Apr. 05, 2028
Expiry date April 5, 2028 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price (in Dollars per share and Dollars per share) | $ / shares		$ 1.077
Expiry date November 23, 2024 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	75	75
Number of shares to be issued from the exercise of warrants	75	75
Exercise price (in Dollars per share and Dollars per share) | $ / shares	$ 1,309.47
Expiry date	Nov. 23, 2024
Expiry date November 23, 2024 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price (in Dollars per share and Dollars per share) | $ / shares		$ 1,800
Expiry date September 17, 2028 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	151,528	151,528
Number of shares to be issued from the exercise of warrants	755,757	755,757
Exercise price (in Dollars per share and Dollars per share) | $ / shares	$ 1.077
Expiry date	Sep. 17, 2028
Expiry date September 17, 2028 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price (in Dollars per share and Dollars per share) | $ / shares		$ 1.077
Expiry date January 15, 2025 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	1,469,800	1,469,800
Number of shares to be issued from the exercise of warrants	1,469,800	1,469,800
Exercise price (in Dollars per share and Dollars per share) | $ / shares	$ 1.6
Expiry date	Jan. 15, 2025
Expiry date January 15, 2025 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price (in Dollars per share and Dollars per share) | $ / shares		$ 1.6

Stock Options (Details)

Stock Options (Details) - USD ($)		3 Months Ended		6 Months Ended
	Nov. 14, 2023	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Stock Options [Line Items]
Issued and outstanding common shares	20%			2%
Options vest expiration	10 years
Share-based compensation expense.		$ 23,292	$ 22,804	$ 56,870	$ 121,935
Bottom of Range [Member]
Stock Options [Line Items]
Issued and outstanding common shares				5%
Top of range [member]
Stock Options [Line Items]
Issued and outstanding common shares				15%

Stock Options (Details) - Sched

Stock Options (Details) - Schedule of Changes in Stock Options	6 Months Ended		12 Months Ended
	Apr. 30, 2024 $ / shares shares	Apr. 30, 2024 $ / shares $ / shares shares	Oct. 31, 2023 $ / shares shares	Oct. 31, 2023 $ / shares shares	Apr. 30, 2024 $ / shares
Schedule of Changes in Stock Options [Abstract]
Number of options Outstanding, Beginning balance (in Shares)	5,588	5,588	5,254	5,254
Weighted average exercise price Outstanding, Beginning balance | (per share)	$ 434.81	$ 603.12	$ 450.64	$ 613.5
Number of options, Granted (in Shares)			334	334
Weighted average exercise price, Granted | (per share)			$ 318.81	$ 442.22
Number of options Outstanding, Ending balance (in Shares)	5,521	5,521	5,588	5,588
Weighted average exercise price Outstanding, Ending balance | (per share)	$ 437.73	$ 601.7	$ 434.81	$ 603.12
Number of options Outstanding, Exercisable (in Shares)	4,803	4,803
Weighted average exercise price Outstanding, Exercisable | (per share)	$ 439.41	$ 439.41			$ 604.01
Number of options, Expired (in Shares)	(67)	(67)
Weighted average exercise price, Expired | (per share)	$ 533.14	$ 720

Stock Options (Details) - Sch_2

Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding	6 Months Ended
	Apr. 30, 2024 $ / shares	Apr. 30, 2024 $ / shares
Stock Outstanding [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	5,521	5,521
Weighted average remaining contractual life (years) Outstanding	5 years 1 month 28 days
Weighted average exercise price Outstanding | (per share)	$ 437.73	$ 601.7
Stock Outstanding [Member] | 533 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	533	533
Weighted average remaining contractual life (years) Outstanding	2 years 25 days
Weighted average exercise price Outstanding | (per share)	$ 121.13	$ 166.5
Stock Outstanding [Member] | 978 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	978	978
Weighted average remaining contractual life (years) Outstanding	7 years 9 months 3 days
Weighted average exercise price Outstanding | (per share)	$ 366.65	$ 504
Stock Outstanding [Member] | 1,166 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	1,166	1,166
Weighted average remaining contractual life (years) Outstanding	2 years 25 days
Weighted average exercise price Outstanding | (per share)	$ 491.05	$ 675
Stock Outstanding [Member] | 200 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	200	200
Weighted average remaining contractual life (years) Outstanding	5 years
Weighted average exercise price Outstanding | (per share)	$ 510.69	$ 702
Stock Outstanding [Member] | 133 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	133	133
Weighted average remaining contractual life (years) Outstanding	2 years 4 months 20 days
Weighted average exercise price Outstanding | (per share)	$ 543.43	$ 747
Stock Outstanding [Member] | 422 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	422	422
Weighted average remaining contractual life (years) Outstanding	7 years 7 months 9 days
Weighted average exercise price Outstanding | (per share)	$ 445.22	$ 612
Stock Outstanding [Member] | 1,044 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	1,044	1,044
Weighted average remaining contractual life (years) Outstanding	7 years 9 months 3 days
Weighted average exercise price Outstanding | (per share)	$ 523.79	$ 720
Stock Outstanding [Member] | 667 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	667	667
Weighted average remaining contractual life (years) Outstanding	2 years 2 months 1 day
Weighted average exercise price Outstanding | (per share)	$ 549.98	$ 756
Stock Outstanding [Member] | 111 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	111	111
Weighted average remaining contractual life (years) Outstanding	7 years 7 months 9 days
Weighted average exercise price Outstanding | (per share)	$ 654.74	$ 900
Stock Outstanding [Member] | 61 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	61	61
Weighted average remaining contractual life (years) Outstanding	9 years 25 days
Weighted average exercise price Outstanding | (per share)	$ 229.16	$ 315
Stock Outstanding [Member] | 156 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	156	156
Weighted average remaining contractual life (years) Outstanding	9 years 1 month 28 days
Weighted average exercise price Outstanding | (per share)	$ 366.65	$ 504
Stock Outstanding [Member] | 50 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	50	50
Weighted average remaining contractual life (years) Outstanding	9 years 2 months 8 days
Weighted average exercise price Outstanding | (per share)	$ 23.4	$ 32.17
Stock Exercisable [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	4,803	4,803
Weighted average exercise price, Exercisable | (per share)	$ 439.41	$ 604.01
Stock Exercisable [Member] | 533 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	489	489
Weighted average exercise price, Exercisable | (per share)	$ 121.13	$ 166.5
Stock Exercisable [Member] | 978 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	795	795
Weighted average exercise price, Exercisable | (per share)	$ 366.65	$ 504
Stock Exercisable [Member] | 1,166 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	1,110	1,110
Weighted average exercise price, Exercisable | (per share)	$ 491.05	$ 675
Stock Exercisable [Member] | 200 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	174	174
Weighted average exercise price, Exercisable | (per share)	$ 510.69	$ 702
Stock Exercisable [Member] | 133 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	133	133
Weighted average exercise price, Exercisable | (per share)	$ 543.43	$ 747
Stock Exercisable [Member] | 422 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	422	422
Weighted average exercise price, Exercisable | (per share)	$ 445.22	$ 612
Stock Exercisable [Member] | 1,044 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	783	783
Weighted average exercise price, Exercisable | (per share)	$ 523.79	$ 720
Stock Exercisable [Member] | 667 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	611	611
Weighted average exercise price, Exercisable | (per share)	$ 549.98	$ 756
Stock Exercisable [Member] | 111 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	93	93
Weighted average exercise price, Exercisable | (per share)	$ 654.74	$ 900
Stock Exercisable [Member] | 61 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	46	46
Weighted average exercise price, Exercisable | (per share)	$ 229.16	$ 315
Stock Exercisable [Member] | 156 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	130	130
Weighted average exercise price, Exercisable | (per share)	$ 366.65	$ 504
Stock Exercisable [Member] | 50 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	17	17
Weighted average exercise price, Exercisable | (per share)	$ 23.4	$ 32.17

Stock Options (Details) - Sch_3

Stock Options (Details) - Schedule of Fair Value of Stock Options - Black-Schole option pricing model [Member]	6 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Schedule of Fair Value of Stock Options [Line Items]
Risk-free interest rate	3.89%	3.89%
Expected life (in years)	5 years 1 month 9 days	5 years 1 month 17 days
Bottom of Range [Member]
Schedule of Fair Value of Stock Options [Line Items]
Expected volatility	150.79%	113%
Top of Range [Member]
Schedule of Fair Value of Stock Options [Line Items]
Expected volatility	161.87%	118%

Restricted Share Units (Details

Restricted Share Units (Details) - USD ($)	6 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 03, 2024	Nov. 06, 2023	Feb. 22, 2023	Feb. 19, 2023	Jan. 16, 2023
Restricted Share Units [Line Items]
Restricted shares units, issued			9,000	45	400	44	161
Fair value consultants	$ 267,346	$ 77,632
RSU's [Member]
Restricted Share Units [Line Items]
Restricted shares units, issued	200,784
Consultants, Directors and Officers [Member] | RSU's [Member]
Restricted Share Units [Line Items]
Restricted shares units, issued	437,765

Restricted Share Units (Detai_2

Restricted Share Units (Details) - Schedule of Changes in RSUs - Restricted Stock Units [Member]	6 Months Ended				12 Months Ended
	Apr. 30, 2024 $ / shares shares		Apr. 30, 2024 $ / shares shares		Oct. 31, 2023 $ / shares shares	Oct. 31, 2023 $ / shares shares
Schedule of Changes in RSUs [Line Items]
Number of RSUs, Beginning balance
Weighted average issue price, Beginning balance | (per share)
Number of RSUs, Granted	437,765	[1]	437,765	[1]	2,200	2,200
Granted, Weighted average issue price, Granted | (per share)	$ 1.29	[1]	$ 1.78	[1]	$ 41.46	$ 55.97
Number of RSUs, Vested	(200,784)		(200,784)		(2,200)	(2,200)
Vested, Weighted average issue price, Vested | (per share)	$ 1.33		$ 1.8		$ 41.46	$ 55.97
Number of RSUs, Ending Balance	236,981		236,981
Weighted average issue price, Ending Balance | (per share)	$ 1.28		$ 1.76
[1]During the six months ended April 30, 2024, the Company issued 437,765 RSU’s to consultants, directors and officers. 200,784 RSU’s vested with a fair value of $267,346 (2023-$77,632).

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Details)	6 Months Ended
	Apr. 30, 2024
Financial Instruments and Risk Management [Line Items]
Foreign currency, percentage	10%
Foreign Exchange Rate Risk [Member]
Financial Instruments and Risk Management [Line Items]
Foreign currency, percentage	10%

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Details) - Schedule of Assets and Liabilities Measured at Fair Value - Recurring fair value measurement [member] - USD ($)	Apr. 30, 2024	Oct. 31, 2023
Financial Instruments and Risk Management [Line Items]
Derivative warrants liability	$ 3,731,799	$ 4,310,379
Short-term investment		86,112
Quoted prices in active markets for identical instruments (Level 1) [Member]
Financial Instruments and Risk Management [Line Items]
Derivative warrants liability
Short-term investment		86,112
Significant other observable inputs (Level 2) [Member]
Financial Instruments and Risk Management [Line Items]
Derivative warrants liability
Short-term investment
Significant unobservable inputs (Level 3) [Member]
Financial Instruments and Risk Management [Line Items]
Derivative warrants liability	$ 3,731,799	4,310,379
Short-term investment

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Details) - Schedule of Foreign Currency Exchange Risk on Net Working Capital - Foreign Exchange Rate Risk [Member]	6 Months Ended
	Apr. 30, 2024 USD ($)
Financial Instruments And Risk Management [Line Items]
Cash and cash equivalents	$ 238,379
Other receivables	49,369
Accounts payable and accrued liabilities	(129,877)
Due to related parties	(37,009)
Total foreign currency financial assets and liabilities	120,862
Impact of a 10% strengthening or weakening of foreign exchange rate	$ 12,086

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Details) - Schedule of Foreign Currency Exchange Risk on Net Working Capital (Parentheticals)	6 Months Ended
	Apr. 30, 2024
Foreign Exchange Rate Risk [Member]
Financial Instruments And Risk Management [Line Items]
Impact of a strengthening or weakening of foreign exchange rate	10%

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Details) - Schedule of Contractual Maturities of Financial Liabilities - USD ($)	Apr. 30, 2024	Oct. 31, 2023
Financial Instruments and Risk Management [Line Items]
Accounts payable and accrued liabilities	$ 421,156	$ 617,004
Due to related parties	47,009	42,433
Total	468,165	659,437
Within 1 year [Member]
Financial Instruments and Risk Management [Line Items]
Accounts payable and accrued liabilities	421,156	617,004
Due to related parties	47,009	42,433
Total	468,165	659,437
Within 2-5 years [Member]
Financial Instruments and Risk Management [Line Items]
Accounts payable and accrued liabilities
Due to related parties
Total

Commitments (Details)

Commitments (Details) - USD ($)	Mar. 30, 2024	Mar. 19, 2024	Jan. 15, 2024
Commitments [Line Items]
Percentage of royalties	3%	3%	2.50%
Annual license fee	$ 25,000	$ 25,000
Payment from company	600,000	600,000
Bottom of range [member]
Commitments [Line Items]
Annual license fee	35,000	35,000
Top of range [member]
Commitments [Line Items]
Annual license fee	50,000	50,000
Yissum Research Development Company [Member]
Commitments [Line Items]
Payment from company	$ 400,000	$ 400,000